Dr. Stephen D. Wiviott is a graduate of University of Pennsylvania (Mathematics, Magna Cum Laude) in 1990 and Harvard Medical School (Honors) in 1996. He served as a Medical House Officer and Chief Medical Resident at Brigham and Women’s Hospital. Following his medical residency training, he served as a Cardiology Fellow at Johns Hopkins Hospital and as a Cardiovascular Research Fellow with the TIMI Study Group with the Cardiovascular Division of Brigham and Women’s Hospital. After completion of his training he has joined the faculty of the Cardiovascular Division of Brigham and Women’s Hospital and serves as Assistant Professor of Medicine at Harvard Medical School, and an investigator with the TIMI Study Group.

As an investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group he has played important roles in the planning, implementation and interpretation of several multicenter, national and international clinical trials. He has played leadership roles in the JUMBO – TIMI 26 trial and the TRITON – TIMI 38 trial the major phase 2 and phase 3 trials of prasugrel a third generation thienopyridine. He was the Principal Investigator of PRINCIPLE – TIMI 44, a study comparing high-dose clopidogrel with prasugrel in patients undergoing PCI and of the TIMI 38 Coronary Stent Registry, an ongoing international registry of the long-term outcomes of patients receiving different types of intracoronary stents for acute coronary syndromes. He was a lead physician for the LANCELOT program evaluating the novel antiplatelet agent atopaxar, a PAR-1 antagonist. He serves as the physician chairman of the TIMI Clinical Events Committee.

In addition, Dr. Wiviott has played major roles in the design and implementation of several trials of lipid lowering therapies in patients with acute coronary syndromes or chronic atherosclerotic disease. These trials include trials of intensive statin therapy PROVE IT – TIMI 22, A to Z TIMI 25 in ACS, and of the cholesteryl esterase transfer protein (CETP) inhibitor anacetrapib in the ongoing REVEAL - HPS 3 – TIMI 55. He also serves as the chairman of the clinical events committee for ongoing lipid studies including IMPROVE IT, a study of ezetemibe vs placebo in ACS, SOLID, a trial of darapladib, an inhibitor or LpPLA2 in patients with ACS and LAPLACE a trial of a novel PCSK9 inhibitor in patients with chronic atherosclerosis.

Dr. Wiviott is an author of more than one hundred peer-reviewed publications in major medical and cardiovascular journals and of multiple chapters in major cardiovascular textbooks including Cardiovascular Therapeutics, a companion to Braunwald’s Heart Disease. He has delivered local, national and international lectures in the field of acute coronary syndromes, platelet biology, established and novel antiplatelet agents and antioagulants. Areas of clinical and research interest include acute coronary syndromes, platelet biology, platelet inhibitors, and cholesterol lowering therapy.

Dr. Wiviott is a general Cardiologist on staff at Brigham and Women’s Hospital attending on the Coronary Care Unit, and the inpatient Cardiology and Cardiology Consultation services. He is active in clinical teaching of Cardiology Fellows, Internal Medicine Housestaff, and Harvard Medical Students. He serves as a faculty member of the teaching faculty of Harvard Medical School.